BR112018013195A2 - composição farmacêutica osmótica oral de vildagliptina - Google Patents

composição farmacêutica osmótica oral de vildagliptina

Info

Publication number
BR112018013195A2
BR112018013195A2 BR112018013195A BR112018013195A BR112018013195A2 BR 112018013195 A2 BR112018013195 A2 BR 112018013195A2 BR 112018013195 A BR112018013195 A BR 112018013195A BR 112018013195 A BR112018013195 A BR 112018013195A BR 112018013195 A2 BR112018013195 A2 BR 112018013195A2
Authority
BR
Brazil
Prior art keywords
vildagliptin
pharmaceutical composition
salt
osmotic pharmaceutical
oral osmotic
Prior art date
Application number
BR112018013195A
Other languages
English (en)
Inventor
Bansal Amit
Sangle Ganesh
Swain Kapileshwar
Madhukar Kodgule Mandar
Saigal Nitin
Gaikwad Sanjay
Kumar Agarwal Sunil
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of BR112018013195A2 publication Critical patent/BR112018013195A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

é fornecida uma composição farmacêutica osmótica compreendendo: (a) um núcleo, compreendendo: (i) uma camada de fármaco compreendendo vildagliptina ou seu sal, e um ou mais excipientes farmaceuticamente aceitáveis; (ii) uma camada de compressão compreendendo óxido de polietileno com um peso molecular de cerca de 5.000.000 a cerca de 8.000.000, em que a razão em peso de vildagliptina ou seu sal e óxido de polietileno varia de cerca de 1:1 a cerca de 1:5; (b) um revestimento de vedação em torno do núcleo; (c) um acetato de celulose de revestimento de liberação sustentada em torno do revestimento de vedação; (d) uma camada de fármaco de liberação imediata compreendendo vildagliptina ou seu sal que envolve o revestimento de liberação sustentada. também é fornecido o processo de preparação de tais composições.
BR112018013195A 2015-12-28 2016-12-23 composição farmacêutica osmótica oral de vildagliptina BR112018013195A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4891MU2015 2015-12-28
PCT/IB2016/057975 WO2017115252A1 (en) 2015-12-28 2016-12-23 An oral osmotic pharmaceutical composition of vildagliptin

Publications (1)

Publication Number Publication Date
BR112018013195A2 true BR112018013195A2 (pt) 2018-12-11

Family

ID=57966046

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013195A BR112018013195A2 (pt) 2015-12-28 2016-12-23 composição farmacêutica osmótica oral de vildagliptina

Country Status (6)

Country Link
KR (1) KR20180092981A (pt)
BR (1) BR112018013195A2 (pt)
MX (1) MX2018007681A (pt)
PH (1) PH12018550075A1 (pt)
RU (1) RU2706706C1 (pt)
WO (1) WO2017115252A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
WO2004024184A1 (ja) 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited 徐放性製剤
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
PT1928499E (pt) 2005-09-20 2011-09-09 Novartis Ag Utilização de um inibidor da dpp-iv para reduzir eventos hipoglicémicos
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
MX2010009731A (es) * 2008-03-04 2010-09-30 Merck Sharp & Dohme Composiciones farmaceuticas de una combinacion de metformina y un inhibidor de dipeptidil peptidasa-iv.
ES2487271T3 (es) 2011-10-06 2014-08-20 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulaciones de dosificación sólidas inhibidoras de DPP-IV
SG11201501014YA (en) 2012-08-23 2015-03-30 Cardiolynx Ag Extended release compositions of an aminoalkyl nitrate

Also Published As

Publication number Publication date
KR20180092981A (ko) 2018-08-20
RU2706706C1 (ru) 2019-11-20
PH12018550075A1 (en) 2019-01-28
MX2018007681A (es) 2018-11-14
WO2017115252A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
PH12019500579A1 (en) Pharmaceutical composition
DOP2016000156A (es) Composiciones farmacã¿uticas que comprenden azd9291.
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
NI201600093A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
BR112012026596A2 (pt) método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
BR112018011266A2 (pt) ?composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica?
BR112019005168A2 (pt) composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112015031417A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
BR112014030160A2 (pt) composição formadora de película, uso de uma composição formadora de película, película e cápsula dura
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
PH12016500693A1 (en) Slow-release solid oral compositions
BR112018013195A2 (pt) composição farmacêutica osmótica oral de vildagliptina
WO2016167605A3 (ko) 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
BR112016010409A8 (pt) composto, composição farmacêutica, combinação, e, uso de um composto e de uma combinação
BR112018069440A2 (pt) forma de dosagem oral
MX2022002185A (es) Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso.
EA201890477A1 (ru) Инкапсулированная композиция финголимода
BR112017022855A2 (pt) combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó
BR112016029417A2 (pt) desmopressina estabilizada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]